Filing Details
- Accession Number:
- 0001567619-19-007289
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-20 14:19:12
- Reporting Period:
- 2019-03-19
- Accepted Time:
- 2019-03-20 14:19:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882361 | Aptose Biosciences Inc. | APTO | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1275087 | Erich Platzer | C/O Aptose Biosciences Inc. 251 Consumers Road, Suite 1105 Toronto A6 M2J 4R3 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2019-03-19 | 15,000 | $2.19 | 130,000 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2019-03-19 | 5,000 | $2.19 | 135,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.18 to $2.19, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.18 to $2.20, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
